

## Original Article

# Early signs that predict later haemodynamically significant patent ductus arteriosus

Defne Engür,<sup>1</sup> Murat Deveci,<sup>2</sup> Münevver K. Türkmen<sup>1</sup>

<sup>1</sup>Department of Neonatology; <sup>2</sup>Department of Pediatric Cardiology, Department of Pediatrics, Adnan Menderes University, Aydın, Turkey

**Abstract** *Objective:* Our aim was to determine the optimal cut-off values, sensitivity, specificity, and diagnostic power of 12 echocardiographic parameters on the second day of life to predict subsequent ductal patency. *Methods:* We evaluated preterm infants, born at  $\leq 32$  weeks of gestation, starting on their second day of life, and they were evaluated every other day until ductal closure or until there were clinical signs of re-opening. We measured transductal diameter; pulmonary arterial diastolic flow; retrograde aortic diastolic flow; pulsatility index of the left pulmonary artery and descending aorta; left atrium and ventricle/aortic root ratio; left ventricular output; left ventricular flow velocity time integral; mitral early/late diastolic flow; and superior caval vein diameter and flow as well as performed receiver operating curve analysis. *Results:* Transductal diameter ( $>1.5$  mm); pulmonary arterial diastolic flow ( $>25.6$  cm/second); presence of retrograde aortic diastolic flow; ductal diameter by body weight ( $>1.07$  mm/kg); left pulmonary arterial pulsatility index ( $\leq 0.71$ ); and left ventricle to aortic root ratio ( $>2.2$ ) displayed high sensitivity and specificity ( $p < 0.0001$ ; area under the curve  $> 0.9$ ). Parameters with moderate sensitivity and specificity were as follows: left atrial to aortic root ratio; left ventricular output; left ventricular flow velocity time integral; and mitral early/late diastolic flow ratio ( $p < 0.05$ ; area under the curve 0.7–0.88). Descending aortic pulsatility index and superior caval vein diameter and flow ( $p > 0.05$ ) had low diagnostic value. *Conclusion:* Left pulmonary arterial pulsatility index, left ventricle/aortic root ratio, and ductal diameter by body weight are useful adjuncts offering a broader outlook for predicting ductal patency.

Keywords: Echocardiography; newborn; patent ductus arteriosus; neonatal intensive care unit; receiver operating characteristic curve method

Received: 22 November 2014; Accepted: 17 February 2015; First published online: 31 March 2015

PATENT DUCTUS ARTERIOSUS IS REPORTED IN approximately one-third of babies weighing 501–1500 g, and almost half of infants weighing  $<1000$  g require medical treatment for symptomatic ductal patency.<sup>1,2</sup> Preterm ductus remains one of the most challenging clinical conditions in neonatology<sup>1–7</sup> because of individual variability regarding the behaviour of the duct<sup>8</sup> and that the benefits of treating larger ducts remain undetermined. Although spontaneous closure is achieved in

most instances by proper metabolic and respiratory management<sup>9</sup> and there is an increasing body of evidence that proposes ductal patency as a secondary phenomenon,<sup>10–12</sup> there is a subgroup of cases in which patent ductus arteriosus results in significant haemodynamic consequences that increase neonatal morbidity and mortality.<sup>13–15</sup>

Considering the systemic effects of cyclooxygenase inhibitors on the developing systems of preterm infants,<sup>16–18</sup> predicting cases that will later achieve spontaneous closure will help avoid unnecessary intervention. On the other hand, given that delayed medical therapy is associated with lower success rates,<sup>19</sup> early identification of preterm infants who

Correspondence to: Dr D. Engür, Adnan Menderes University Department of Neonatology, Aytepe Mevki, 32100, Aydın, Turkey. Tel: +90 256 444 12 56; Fax: +90 256 214 40 86; E-mail: defneka@hotmail.com

subsequently fail to achieve ductal closure allows early initiation of intervention and reduced treatment failure.

The diagnosis of haemodynamically significant ductal patency requires echocardiographic assessment;<sup>20</sup> however, the definition of haemodynamically significant patent ductus arteriosus remains controversial.<sup>21,22</sup> Controversy also remains regarding the benefit of treating patent ductus arteriosus in preterm infants, with studies providing contradictory results.<sup>23</sup>

Our aim was to evaluate preterm infants on the second day of life in order to determine the sensitivity and specificity of twelve separate echocardiographic parameters in infants who subsequently developed haemodynamically significant patent ductus arteriosus compared with those who spontaneously achieved ductal closure and to identify those who require subsequent intervention. We also aimed to identify the optimal cut-off value with the lowest rate of misclassification for each echocardiographic parameter on the second day of life, and we compared the diagnostic performances of these markers as well.

## Materials and methods

This prospective study was approved by the institutional ethics committee of Adnan Menderes University Hospital, and infants were enrolled to the study after obtaining written parental consent. The study was conducted at the neonatal intensive care unit of Adnan Menderes University Hospital. We included preterm infants born at  $\leq 32$  weeks of gestational age and they were followed-up during the period between January, 2012 and 2013. We excluded patients who died in the first week of life and those who had major congenital abnormalities, grade 3 or 4 intra-ventricular haemorrhage, or congenital cardiac malformations. The outcome of interest was the sensitivity and specificity of the echocardiographic measurements to identify individuals requiring intervention when comparing infants who subsequently developed haemodynamically significant patent ductus arteriosus with those who successfully achieved ductal closure.

Blood cultures using 1 ml blood sample at birth, complete blood count, peripheral smear, and serum C-reactive protein measurements at six hours of life were performed as part of the routine premature care in our unit. Serum C-reactive protein levels were measured with a commercially available kit using the turbidimetric method (Tokyo Boeiki, Prestige 24i, Tokyo, Japan). Early onset neonatal sepsis was defined as clinical sepsis in the first 48 hours after birth, with elevated immature/total neutrophil count, C-reactive protein, and positive blood culture.<sup>24</sup> Empirical antibiotic choices for preterm infants were ampicillin

and gentamicin. Nasal continuous positive airway pressure or mechanical ventilation was initiated, depending on the severity of respiratory distress, and a surfactant (Survanta<sup>®</sup>, Abbot Laboratories, Chicago, Illinois, United States of America) was administered to babies with respiratory distress syndrome within the first 2 hours of life at a dose of 4 ml/kg.

In all cases, parenteral nutrition was initiated on the first day at 100 ml/kg/day initially, and was increased by 20 ml/kg/day up to 160–180 ml/kg/day based on urinary output and density. Along with parenteral nutrition, enteral feeding was initiated on the first day of life and was increased gradually. Dopamine was used if blood pressure dropped below the fifth percentile for gestational and postnatal age.<sup>25</sup>

### *Echocardiography measurements*

Echocardiographic evaluation was performed by a single paediatric cardiologist, starting on the second day of the infant's life, and cases were subsequently followed-up every other day until ductal closure was achieved or until there were clinical signs of re-opening – that is, re-appearance of any of the clinical signs of ductus arteriosus. Measurements were performed with an ultrasonography system (HD11 XE; Philips Medical Systems, Eindhoven, the Netherlands) using an 8–13 MHz transducer. We measured the following parameters: transductal diameter; pulmonary arterial diastolic flow; presence of retrograde diastolic flow in the aorta; ductal diameter by body weight; left pulmonary artery pulsatility index; left ventricle to aortic root ratio; left atrium to aortic root ratio; left ventricular output; left ventricular flow velocity time integral; mitral early/late diastolic flow ratio; descending aorta pulsatility index; and superior caval vein diameter and flow. Infants were placed in the supine position during the echocardiographic assessment without sedation. Ductal diameters were measured using two-dimensional and colour flow at the pulmonary end, the median section, and the aortic end of the ductus on high left parasternal view. The size of the ductus was measured in mm at its narrowest part on a colour Doppler image. The ductal gradient was obtained using continuous wave Doppler. Peak systolic velocity less than 2 m/second was considered as a sign of non-restrictive pulsatile flow.<sup>26,27</sup>

M-mode measurements of the left atrium/aortic root and left ventricle/aortic root (left atrium/left ventricle) ratios and two-dimensional measurements of the left ventricle and ductus arteriosus diameters were assessed from parasternal views. Aortic and left pulmonary arterial blood flows, transmitral inflow, and ductal shunting data were obtained by Doppler studies.<sup>28,29</sup>

In the apical four-chamber view, peak early filling velocity, peak atrial systolic velocity, and early/late

diastolic flow ratio were recorded for the mitral valve by placing the Doppler sample volume at the tip of the mitral valve.<sup>30</sup>

The superior caval vein flow velocity time integral was assessed from a low sub-costal view.<sup>31</sup> The diameter of the superior caval vein was obtained by M-mode echocardiography from the right or left parasternal long-axis view at the junction of the superior caval vein and the right atrium. The mean of the maximum and minimum diameter was recorded. Superior caval vein flow was calculated as follows:<sup>31</sup>

Superior caval vein flow (ml/kg/minute) = (heart rate  $\times$  superior caval vein cross-sectional area  $\times$  superior caval vein velocity time integral)/body weight.

The diameter of the left ventricular outflow tract was imaged from a parasternal long-axis view, using the leading edge technique. The flow velocity time integral was assessed from the apical view with the sample volume placed in the ascending aorta.<sup>28,32,33</sup>

The heart rate was quantified from peak-to-peak intervals of the Doppler velocity time signals. Left ventricular output was calculated using the following formula:<sup>28</sup>

Left ventricular output (ml/kg/minute) = (heart rate  $\times$  aortic cross-sectional area  $\times$  aortic velocity time integral)/body weight.

Descending aorta flow velocity time integral was assessed twice, both from a low sub-costal and a high parasternal sagittal view. Any reversal of diastolic flow in the descending aorta was taken into consideration, and was subtracted from the antegrade flow to reveal an integrated velocity time integral. Systolic and diastolic descending aorta diameters were assessed by M-mode echocardiography using the trailing edge-leading edge procedure.<sup>33</sup>

Left pre-ejection period was described as the time from the start of the QRS complex on electrocardiography to the opening of the aortic valve on a long-axis M-mode view. Left ventricular ejection time was determined by measuring the time between aortic valve opening and closure from a pulse-wave aortic Doppler trace. The left pre-ejection period/left ventricular ejection time ratio accounted for the left ventricular systolic time interval.<sup>32</sup> The pulsatility index of the left pulmonary artery and that of the descending aorta were calculated as follows:<sup>34</sup>

Pulsatility index = (peak systolic velocity - peak diastolic velocity)/peak systolic velocity.

All the echocardiographic data were digitally recorded and reviewed subsequently by the same investigator. Measurements for all 12 parameters were repeated twice in a random subset of 15 patients with the second measurement performed after a 30-minute interval. The intra-observer variability had an overall mean percentage difference of  $2.9 \pm 1.6\%$ .

### *Diagnosis of haemodynamically significant patent ductus arteriosus*

Although the definition of a haemodynamically significant duct varies in randomised controlled trials, we chose the four most commonly used parameters.<sup>21–22</sup> Infants who fulfilled all of the four following criteria on day 5 were diagnosed as having haemodynamically significant patent ductus arteriosus:<sup>22</sup> ductal diameter  $>1.5$  mm with left-to-right shunt; left atrium/aortic root ratio  $>1.5$ ; diastolic flow in the pulmonary artery  $>0.20$  m/second; and the presence of retrograde diastolic flow in the aorta. In the event where a haemodynamically significant patent ductus arteriosus was detected, treatment decisions were made according to the infant's clinical status. Increased respiratory distress, need for increased mechanical ventilation parameters, apnoea, resting tachycardia, metabolic acidosis, hyperdynamic precordium, bounding pulses, systolic or continuous murmur at the upper left sternal border, hypotension, signs of pulmonary oedema on chest X-ray, or pink secretions from the endotracheal tube were the clinical signs considered for treatment decisions. Oral ibuprofen (Pedifen<sup>®</sup>, Atafarm, Istanbul, Turkey) was administered for medical treatment (initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 hours).

### *Statistical analysis*

Statistical analysis was performed using MedCalc statistical software (MedCalc Software, Belgium). Comparison was carried out using Fisher's exact test for nominal variables and the Mann–Whitney independent samples U-test for continuous variables. The Bland–Altman test was used to calculate intra-observer variability. Sensitivity, specificity, positive and negative likelihood ratios, and best cut-off values were calculated by obtaining the receiver operating characteristic curves for each echocardiographic parameter. The area under the receiver operating characteristic curve ranged from 0.50 to 1.00, depending on the efficiency of the test. The larger the area under the curve, the better the differentiation power of the test.<sup>35</sup> We computed the sample size for cases with and without patent ductus arteriosus as 10/40 with type I error at 0.05 and type II error rate  $\leq 0.10$  (power  $\geq 0.90$ ) if the area under the curve was  $>0.80$ .<sup>36</sup>

### **Results**

There were 427 infants hospitalised during the study period, and 58 infants were  $\leq 32$  weeks of gestational age during the study period. Of these, three were excluded because of congenital cardiac malformation

Table 1. Demographic characteristics in the two groups.

	PDA group (n = 12)	Ductal closure group (n = 41)	p
Birth weight (g)	1060 (995–1420)	1410 (1112–1707)	0.019
Gestational age (weeks)	29 (28.5–30)	30 (29–31)	0.07
Male gender	8 (66)	23 (56)	0.7
Vaginal delivery	2 (17)	11 (26)	0.7
Apgar score at 5th minute	9 (8–9)	8 (8–9)	0.29
Premature rupture of membranes	0	2 (5)	1
Antenatal betamethasone usage	5 (42)	15 (36)	0.7
Chorioamnionitis	2 (17)	3 (7)	0.3
Small for gestational age	1 (8)	1 (2)	0.4
Respiratory distress syndrome	12 (100)	26 (63)	0.01
Need for mechanical ventilation on day 2	11 (91)	25 (60)	0.04
CRP	0.82 (0.3–36)	0.18 (0.2–8)	0.2
Early onset sepsis	2 (17)	3 (7)	0.3

CRP = C-reactive protein; PDA = patent ductus arteriosus

Quantitative data are presented as median (IQR) and qualitative data as counts (percentages)

and two cases were excluded because of death on the second day of life and presence of grade 4 intra-ventricular haemorrhage. A total of 53 infants were finally eligible for evaluation.

The infants' demographic data are shown in Table 1. Of the 53 infants enrolled in our study, 12 (22%) were diagnosed with haemodynamically significant patent ductus arteriosus based on the echocardiographic assessment on days 5–7; three infants required dopamine treatment for hypotension, and all three were in the patent ductus arteriosus group. Ductal closure was achieved in eight cases with a single course of oral ibuprofen, four cases required a second course, and none of the infants required surgical intervention.

The demographic findings are summarised in Table 1. Echocardiographic parameters on the second day are shown in Table 2, with the parameters compared using a receiver operating characteristic curve analysis (Table 3). Transductal diameter; pulmonary arterial diastolic flow; retrograde aortic diastolic flow; ductal diameter by body weight; left pulmonary artery pulsatility index; and left ventricle to aortic root ratio had high sensitivity and specificity ( $p < 0.0001$ , area under the curve  $> 0.9$ ). Parameters that displayed moderate sensitivity and specificity on the second day were left atrial to aortic root ratio; left ventricular output; left ventricular flow velocity time integral; and mitral early/late diastolic flow ratio ( $p < 0.05$ ; area under the curve, 0.7–0.88). Parameters that displayed low sensitivity and specificity on the second day were descending aortic pulsatility index and superior caval vein diameter and flow ( $p > 0.05$ ).

## Discussion

We compared 12 echocardiographic parameters on the second day after birth using a receiver operating

characteristic curve analysis. Our results showed that ductal diameter by body weight, left pulmonary artery pulsatility index, and left ventricle/aortic root parameters on the second day had excellent sensitivity and specificity for identifying those infants requiring subsequent intervention.

Johnson et al<sup>37</sup> evaluated 3559 premature infants shortly after birth and compared the echocardiographic parameters of 415 infants who subsequently developed clinically significant patent ductus arteriosus with those of 1496 infants without signs of haemodynamically significant patent ductus arteriosus. The authors stated that the best discrimination between the two groups was provided by a left atrium/aortic root ratio of 1.40, a left ventricle/aortic root ratio of 2.10, or a left ventricular systolic time interval of 0.27. Multivariate analysis demonstrated that better separation between the two groups occurred when the left atrium/aortic root ratio and left ventricular systolic time interval were considered jointly. The authors also suggested that echocardiographic variables should be used together to improve the power of this diagnostic tool, as there was a large degree of overlap between the normal group and the group with patent ductus arteriosus. We found similar cut-off points for left atrial and left ventricle to aortic root ratios; however, left ventricle to aortic root ratio appears to have better diagnostic relevance than the latter (area under the curve values were 0.94 and 0.88, respectively).

Sehgal and McNamara<sup>32</sup> found that left ventricular systolic time interval closely correlated with myocardial function, and they proposed this parameter as an alternative method of assessing left ventricular performance. As ductal patency results in reduced left pre-ejection period and increased left ventricular ejection time, an overall decline in left ventricular systolic time interval is expected.<sup>32</sup>

Table 2. Echocardiographic parameter measurements in the two groups on the second day of life.

	PDA group			Ductal closure group			p
	Median	IQR	Minimum–maximum	Median	IQR	Minimum–maximum	
Ductal diameter (mm)	1.8	(1.6–1.95)	(1.2–2.1)	0	(0)	(0–1.6)	<0.0001
Ductal velocity (cm/second)	173.5	(142–251.5)	(118.6–300)	0	(0)	(0–312.5)	<0.0001
Ductal diameter per weight (mm/kg)	1.6	(1.2–1.9)	(1.1–2.1)	0	(0)	(0–1.1)	<0.0001
Left pulmonary artery diastolic flow (cm/second)	48.6	(43.9–58)	(27.9–71.1)	13.6	(10.8–19.2)	(4.4–74.9)	<0.0001
Left atrium/aortic root	1.54	(1.4–1.8)	(1.1–2.1)	1.23	(1.1–1.3)	(0.98–1.44)	0.0001
Left ventricle/aortic root	2.52	(2.3–2.6)	(2.23–2.7)	2.07	(1.96–2.1)	(1.43–2.9)	<0.0001
Mitral early/late diastolic flow ratio	0.9	(0.79–1)	(0.75–1.3)	0.75	(0.68–0.84)	(0.71–0.83)	0.003
Left ventricle velocity time integral	0.15	(0.12–0.18)	(0.09–0.3)	0.2	(0.18–0.24)	(0.1–0.37)	0.0054
Retrograde diastolic flow (%)	30	(16.9–41)	(0–71)	0	(0)	(0–32)	<0.0001
Aortic stroke volume (ml/kg)	1.53	(1.4–1.7)	(0.9–2.2)	1.42	(1.17–1.57)	(0.8–2.9)	0.15
Left ventricle output (ml/kg/minute)	266.3	(218–295)	(156–393)	207.7	(175–239)	(127–421)	0.028
Superior caval vein diameter	0.23	(0.19–0.26)	(0.15–0.52)	0.26	(0.23–0.31)	(0.18–0.44)	0.07
Superior caval vein flow	77.4	(56–130)	(34–500)	75.9	(55–126.6)	(24–359)	0.86
Left ventricle output/superior caval vein flow	3.7	(1.8–5.4)	(0.3–9)	2.6	(1.5–3.9)	(0.6–10.8)	0.20
Pulsatility index of left pulmonary artery	0.58	(0.49–0.65)	(0.4–0.6)	0.84	(0.80–0.88)	(0.6–0.94)	<0.0001
Pulsatility index of descending aorta	1	(0.78–1)	(0.26–1)	0.84	(0.81–0.86)	(0.6–1)	0.1

IQR = interquartile range; PDA = patent ductus arteriosus

Table 3. Comparison of the echocardiographic markers by receiver operating characteristic curves.

	AUC	%95 CI	Cut-off	Sensitivity	Specificity	+LR	-LR	p
Ductal diameter	0.98	0.89–0.99	>1.5	83.3	97.5	34.1	0.2	<0.0001
Left atrium/aortic root	0.89	0.76–0.95	>1.36	100	82.9	5.9	0	<0.0001
Diastolic flow in pulmonary artery	0.97	0.88–0.99	>25.6	100	92.7	13.6	0	<0.0001
Retrograde diastolic flow	0.91	0.79–0.96	>0	83.3	97.5	34.1	0.2	0.0001
Ductal diameter by weight	0.98	0.91–1	>1.07	100	95.1	20.5	0	<0.0001
Pulsatility index of left pulmonary artery	0.97	0.88–0.99	≤0.71	100	90.2	10.2	0	<0.0001
Left ventricle/aortic root	0.94	0.83–0.98	>2.2	100	82.9	5.9	0	<0.0001
Mitral early/late diastolic flow ratio	0.78	0.64–0.87	>0.74	100	43.9	1.8	0	<0.0001
Left ventricle velocity time integral	0.77	0.63–0.87	≤0.18	83.3	68	2.6	0.2	0.003
Left ventricle output	0.71	0.56–0.82	>247.8	66.6	82.9	3.9	0.4	0.025

AUC = area under curve; CI = confidence interval; LR = Likelihood ratio

Left ventricular systolic time interval had an area under the curve of 0.77 in our study. Similarly, the area under the curve for left ventricular output/superior caval vein ratio was also low in our study. Kluckow and Evans previously found that left ventricular output/superior caval vein flow had a high correlation with diastolic flow rate in the duct, left atrium/aortic root, ductal diameter, and average flow velocity in the left pulmonary artery before the second day of life,<sup>31</sup> and proposed that, as it is directly proportional to ductal flow, left ventricular output/superior caval vein flow should be considered an additional precise indicator for the magnitude of the ductal shunt. El Hajjar et al,<sup>28</sup> assessing the relationship between left ventricular output/superior caval vein ratio and left atrium/aortic root ratio, diameter of the ductus, and the mean end-diastolic

flow velocity of the left pulmonary artery on the second day of life, also suggested left ventricular output/superior caval vein ratio as an ideal criterion for evaluating patent ductus arteriosus. The authors found an area under the curve for left ventricular output/superior caval vein ratio of 0.94, and recommended a cut-off point of ≥4. In our study, the median value for this parameter was 3.7 in the ductus arteriosus group. Left ventricular output also had a lower sensitivity and specificity to predict haemodynamically significant ductus in our study (area under the curve for left ventricular output, 0.79).

Pulsatility index refers to a variable reflecting the downstream resistance to blood flow in the vascular bed; therefore, the pulsatility index of the left pulmonary artery provides insight into right ventricular contractility, pre-load, and afterload.<sup>37</sup> We found

that when the left pulmonary artery pulsatility index was  $<0.72$  on the second day of life, it was highly probable that future intervention would be required, with a sensitivity of 100% and a specificity of 90.2%. Our findings are consistent with those of Freeman et al,<sup>34</sup> who proposed dividing the pulsatility index of the left pulmonary artery by that of the descending aorta as a precise indicator of ductal shunting. The authors discussed that minimal shunting is possible with a large duct and emphasised the importance of the amount of shunting for accurate assessment; however, they evaluated their study group based on suspected haemodynamically significant patent ductus arteriosus at different times, ranging from 0 to 29 days of life. The haemodynamic situation of the duct can be influenced by time and by alterations in the pulmonary dynamics after birth. In contrast, we evaluated the pulsatility indices of the left pulmonary artery and descending aorta on one specific day – the second day of life – and before the clinical signs of haemodynamically significant patent ductus arteriosus developed. We found pulsatility index of the left pulmonary artery to be a highly valuable indicator, with an area under the curve of 0.97, whereas the pulsatility index of the descending aorta was not relevant. The sensitivity of the index to changes in pulmonary arterial resistance and compliance should be investigated further.

A possible explanation for the discrepancy between our results and previous reports may be variation in the parameters with respiration and the impact of mechanical ventilation on measurement quality. Infants with patent ductus arteriosus, when compared with infants who successfully achieve ductal closure, usually have lower gestational age, more frequent respiratory distress syndrome, and a need for mechanical ventilation. The presence of respiratory distress syndrome and the use of mechanical ventilation may alter pulmonary vascular resistance and have a remarkable influence on left-to-right shunting through the open ductus.<sup>26</sup> Intra-observer and inter-observer variability are also limitations in ductal studies, making it difficult to draw final conclusions from a particular study or to make comparisons between studies.

A second reason for the difference in our results compared with previous studies is that we included patients with gestational age ranging from 26 to 32 weeks; however, the more immature the baby, the more time it takes for it to be stabilised haemodynamically. Relatively, mature infants usually need less inotropic and pulmonary support and they face less metabolic and biochemical derangements, resulting in different consequences, interfering with ongoing ductal closure at the cellular level. Immature babies not only have different lung mechanics but

also require different fluid protocols. The behavioural pattern of the duct may also vary in babies at different stages of maturation. Sonographic examination of the ductus on the second day of life may reveal a totally different dynamic picture between, for instance, a baby at 26 weeks of gestation and one at 32 weeks of gestation. A comparison of measurements carried out at less than 28 weeks with those carried out at greater than 28 weeks would be helpful; however, given that the most important predictor of ductal patency is gestational age, a more comprehensive approach would be to classify cases according to their degree of maturation, instead of including all premature cases below a particular gestational week in a single group. Perhaps, every echocardiographic parameter should be evaluated relative to the specific gestational age, which would facilitate comparisons of the data gathered from studies with different designs.

Another possible improvement to our study would be having a second cardiologist perform the final echocardiographic assessment, blinded to the previous sonographic findings. This approach could have avoided errors arising from bias, but it was not feasible for our study group because there was only one paediatric cardiologist in our centre during the study period.

Early intervention for haemodynamic consequences of left-to-right shunting across the ductus, including pulmonary over-circulation and systemic (particularly cerebral) hypoperfusion, decreases the risk of respiratory and neurologic morbidities in preterm infants. On the other hand, if early prophylaxis is given to all preterm infants, more than half will be exposed to the side-effects of cyclooxygenase inhibitors unnecessarily because spontaneous closure is achieved in most instances.<sup>23</sup> Regarding ductal patency, both the ideal timing and the necessity for treatment remain to be determined.<sup>23</sup> Earlier and accurate identification of cases requiring subsequent medical intervention from those that can be managed with watchful waiting will greatly help the practicing clinician to develop individualised therapeutic strategies.

## Conclusion

We identified the optimal cut-off points for echocardiographic markers on the second day of life to predict subsequent ductal patency. We suggest that left pulmonary arterial pulsatility index, left ventricle/aortic root ratio, and left pulmonary artery diastolic flow are useful adjuncts to conventional variables to predict haemodynamically significant patent ductus arteriosus. These indicators can offer a broader outlook when used with conventional parameters.

## Acknowledgements

None.

## Financial Support

This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.

## Conflicts of Interest

None.

## Ethical Standards

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national guidelines on human experimentation (Turkey) and with the Helsinki Declaration of 1975, as revised in 2008, and has been approved by the institutional committee (Adnan Menderes University Hospital).

## References

1. Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. *Pediatrics* 2010; 125: 1020–1030.
2. Sehgal A, McNamara PJ. The ductus arteriosus: a refined approach. *Semin Perinatol* 2012; 36: 105–113.
3. Clyman RI, Couto J, Murphy GM. Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all? *Semin Perinatol* 2012; 36: 123–129.
4. Benitz WE. Patent ductus arteriosus: to treat or not to treat? *Arch Dis Child Fetal Neonatal Ed* 2012; 97: 80–82.
5. Chawla D. Patent ductus arteriosus: looking for the right approach of management. *Indian Pediatr* 2012; 49: 611–612.
6. El-Khuffash A, Mertens L. Early treatment of the patent ductus arteriosus: do we know what we are doing? *Pediatr Crit Care Med* 2012; 13: 363–364.
7. Sehgal A. Haemodynamically unstable preterm infant: an unresolved management conundrum. *Eur J Pediatr* 2011; 170: 1237–1245.
8. Lai LS, McCrindle BW. Variation in the diagnosis and management of patent ductus arteriosus in premature infants. *Pediatr Child Health* 1998; 3: 405–410.
9. Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. *Pediatrics* 2006; 117: 1113–1121.
10. Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? *J Perinatol* 2010; 30: 241–252.
11. Bose CL, Laughon MM. Patent ductus arteriosus: lack of evidence for common treatments. *Arch Dis Child Fetal Neonatal Ed* 2007; 92: 498–502.
12. Laughon MM, Simmons MA, Bose CL. Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated? *Curr Opin Pediatr* 2004; 16: 146–151.
13. Evans NJ, Kluckow M. Early significant ductal shunting and intraventricular haemorrhage in ventilated preterm infants. *Arch Dis Child* 1996; 75: 183–186.
14. Kluckow M, Evans NJ. High pulmonary blood flow, the duct and pulmonary haemorrhage. *J Pediatr* 2000; 137: 68–72.
15. Noori S, McCoy M, Friedlich P, et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. *Pediatrics* 2009; 123: 138–144.
16. Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli FF. Effects of indomethacin and ibuprofen on mesenteric

- and renal blood flow in preterm infants with patent ductus arteriosus. *J Pediatr* 1999; 135: 733–738.
17. Sehgal A, Ramsden CA, McNamara PJ. Indomethacin impairs coronary perfusion in infants with hemodynamically significant ductus arteriosus. *Neonatology* 2012; 101: 120–127.
18. Patel J, Roberts I, Azzopardi D, Hamilton P, Edwards AD. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. *Pediatr Res* 2000; 47: 36–42.
19. Abdel-Hady H, Nasef N, Shabaan AE, Nour I. Patent ductus arteriosus in preterm infants: do we have the right answers? *Biomed Res Int* 2013; 2013: 676192.
20. Evans N. Echocardiographic assessment of the patent ductus arteriosus in the preterm infant. In Poets CF, Franz A, Koehne P (eds), *Controversies Around Treatment of the Open Duct*. Springer-Verlag, Berlin-Heidelberg, 2011, pp 37–54.
21. De Waal KA, Zonnenberg I. The definition of a hemodynamic significant duct in randomized controlled trials: a systematic literature review. *Acta Paediatr* 2012; 101: 247–251.
22. McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. *Arch Dis Child Fetal Neonatal Ed* 2007; 92: 424–427.
23. Sinha B. Controversies in management of patent ductus arteriosus in the preterm infant. *J Pulmon Resp Med* 2013; S13: 007.
24. Polin RA. Committee on Fetus and Newborn. Management of neonates with suspected or proven early-onset bacterial sepsis. *Pediatrics* 2012; 129: 1006–1015.
25. Cayabyab R, McLean CW, Seri I. Definition of hypotension and assessment of hemodynamics in the preterm neonate. *J Perinatol* 2009; 29: 58–62.
26. Kluckow M, Evans N. Early echocardiographic prediction of symptomatic patent ductus arteriosus in preterm infants undergoing mechanical ventilation. *J Pediatr* 1995; 127: 774–779.
27. Evans N, Iyer P. Assessment of ductus arteriosus shunt in preterm infants requiring ventilation: effect of interatrial shunt. *J Pediatr* 1994; 125: 778–785.
28. El Hajjar M, Vaksman G, Rakza T, Kongolo G, Storme L. Severity of the ductal shunt: a comparison of different markers. *Arch Dis Child Fetal Neonatal Ed* 2005; 90: 419–422.
29. Suzmura H, Nitta A, Tanaka O. Diastolic flow velocity of left pulmonary artery of patent ductus arteriosus in preterm infants. *Pediatr Int* 2001; 43: 146–151.
30. Schmitz L, Stiller B, Koch H, et al. Diastolic left ventricular function in preterm infants with a patent ductus arteriosus: a serial Doppler echocardiography study. *Early Hum Dev* 2004; 76: 91–100.
31. Kluckow M, Evans N. Superior vena cava flow in newborn infants: a novel marker of systemic blood flow. *Arch Dis Child Fetal Neonatal Ed* 2000; 82: 182–187.
32. Sehgal A, McNamara PJ. Does echocardiography facilitate determination of hemodynamic significance attributable to the ductus arteriosus? *Eur J Pediatr* 2009; 168: 907–914.
33. Groves AM, Kuschel CA, Knight DB, Skinner JR. Echocardiographic assessment of blood flow volume in the superior vena cava and descending aorta in the newborn infant. *Arch Dis Child Fetal Neonatal Ed* 2008; 93: 24–28.
34. Freeman-Ladd M, Cohen JB, Carver JD, et al. The hemodynamic effects of neonatal patent ductus arteriosus shunting on superior mesenteric artery blood flow. *J Perinatol* 2005; 25: 459–462.
35. Moons KG, de Groot JA, Linnet K, Reitsma JB, Bossuyt PM. Quantifying the added value of a diagnostic test or marker. *Clin Chem* 2012; 58: 1408–1417.
36. Obuchowski NA, Lieber ML, Wians FH, Jr. ROC curves in clinical chemistry: uses, misuses, and possible solutions. *Clin Chem* 2004; 50: 1118–1125.
37. Johnson GL, Breart GL, Gewitz MH, et al. Echocardiographic characteristics of premature infants with patent ductus arteriosus. *Pediatrics* 1983; 72: 864–871.